Over the past decade, the assessment of dihydropyrimidine dehydrogenase (DPD) activity has become standard of care for all cancer patients who are candidate to receive 5-fluorouracil (5-FU)-based chemotherapy combinations [1–3]. The gene discussed is DPYD; the disease is cancer.